Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Duodenal Neoplasms 1Colorectal Neoplasms 1Barrett Esophagus 1Attenuated familial adenomatous polyposis 1Adenomatous Polyposis Coli 1Adenocarcinoma Of Esophagus 1

Interventions

Paclitaxel 6Radiotherapy 5Fluorouracil 5Cisplatin 4Taxes 3Specimen Handling 3Radiation 2Erlotinib Hydrochloride 2Endoscopy, Digestive System 2Endoscopy 2trastuzumab biosimilar HLX02 1rubitecan 1romidepsin 1oblimersen 1obeticholic acid 1cixutumumab 1bryostatin 1 1alvocidib 1adavosertib 1Trastuzumab 1Ramucirumab 1Radiofrequency Ablation 1PF-05280014 1Oxaliplatin 1Ontruzant 1Ogivri 1Nivolumab 1Neoadjuvant Therapy 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Adenocarcinoma Of Esophagus × obeticholic acid × Clear all
NCT04939051 2026-05-13

Obeticholic Acid for Prevention in Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡